sprite-preloader
Samstag, 21.01.2017 Börsentäglich über 12.000 News von 554 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von Pharmaceutical Business Review

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrCytori to buy Azaya's nanoparticle Development Platform
FrAbeona gets orphan drug status in EU for ABO-101 gene therapy in Sanfilippo syndrome type B
FrEthypharm agrees to acquire UK-based Martindale Pharma
FrFDA approves Imbruvica for relapsed/refractory marginal zone lymphoma
FrOtonomy starts patient enrollment in phase 2 trial of OTO-104
DoProMetic's alstrom syndrome treatment gets orphan drug status in Europe
DoaTyr Pharma's Resolaris secures FDA fast track status
DoMallinckrodt to pay $100m to settle US charges on drug pricing
DoTakeda, Ovid to co-develop rare pediatric epilepsy candidate TAK-935
DoEMA and FDA to review Boehringer's biosimilar candidate to Humira
DoLilly to buy CoLucid Pharmaceuticals for $960m
MiEuropean Commission approves Suliqua to treat adults with type 2 diabetes
MiBiogen to pay Forward Pharma $1.25bn to settle multiple sclerosis drug case
MiClinigen begins US Managed Access program for TESARO's niraparib in ovarian cancer patients
MiEvgen Pharma doses first patient in phase II breast cancer trial
MiAstraZeneca refines endpoints in immuno-oncology trials for NSCLC
DiMonoSol Rx files patent infringement case against BioDelivery Sciences International
DiHorizon Discovery broadens gene editing capabilities
DiChi-Med starts phase II study of sulfatinib in second-line biliary tract cancer in China
DiMalin buys 33% interest in UK's Wren Therapeutics
DiScottish Medicines Consortium approves Zepatier to treat chronic hepatitis C
MoAptevo Therapeutics receives $20m payment from Emergent BioSolutions
MoObsEva completes phase 1 first-in-women study of OBE022 to treat preterm labor
MoNivalis Therapeutics unveils corporate restructuring
MoFDA extends review period by three months for rheumatoid arthritis candidate baricitinib